First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [41] Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis
    Di Nunno, Vincenzo
    De Luca, Emmanuele
    Buttigliero, Consuelo
    Tucci, Marcello
    Vignani, Francesca
    Gatto, Lidia
    Zichi, Clizia
    Ardizzoni, Andrea
    Di Maio, Massimo
    Massari, Francesco
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 124 - 132
  • [42] PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience
    Nasr, Sarah
    Haddad, Fadi G.
    Khazen, Joseph
    Kattan, Joseph
    Trak-Smayra, Viviane
    BMC CANCER, 2023, 23 (01)
  • [43] Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
    Wang, Di
    Sun, Kai
    Wang, Tianqi
    Zhang, Dongxu
    Sun, Fengze
    Cui, Yuanshan
    Zhao, Hongwei
    Wu, Jitao
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [44] Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
    Hsu, Miles M.
    Xia, Yuhe
    Troxel, Andrea
    Delbeau, Daniela
    Francese, Kaitlyn
    Leis, Dayna
    Shepherd, Deneuve
    Balar, Arjun, V
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : E209 - E216
  • [45] Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer
    de Liano Lista, Alfonso Gomez
    van Dijk, Nick
    Oria de Rueda, Guillermo de Velasco
    Necchi, Andrea
    Lavaud, Pernelle
    Morales-Barrera, Rafael
    Alonso Gordoa, Teresa
    Maroto, Pablo
    Ravaud, Alain
    Duran, Ignacio
    Szabados, Bernadett
    Castellano, Daniel
    Giannatempo, Patrizia
    Loriot, Yohann
    Carles, Joan
    Anguera Palacios, Georgia
    Lefort, Felix
    Raggi, Daniele
    Goupil, Marine Gross
    Powles, Thomas
    Van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2020, 77 (02) : 269 - 276
  • [46] Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Piperdi, Bilal
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (18) : 1541 - 1554
  • [47] Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
    Makrakis, Dimitrios
    Talukder, Rafee
    Lin, Genevieve Ihsiu
    Diamantopoulos, Leonidas N.
    Dawsey, Scott
    Gupta, Shilpa
    Carril-Ajuria, Lucia
    Castellano, Daniel
    de Kouchkovsky, Ivan
    Koshkin, Vadim S.
    Park, Joseph J.
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler F.
    Mckay, Rana R.
    Tripathi, Nishita
    Agarwal, Neeraj
    Vather-Wu, Naomi
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael E.
    Cortellini, Alessio
    Fulgenzi, Claudia Angela Maria
    Pinato, David J.
    Nelson, Ariel
    Hoimes, Christopher J.
    Gupta, Kavita
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Murgic, Jure
    Frobe, Ana
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Lu, Eric
    Kumar, Vivek
    Di Lorenzo, Giuseppe
    Joshi, Monika
    Isaacsson-Velho, Pedro
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Jang, Albert
    Barata, Pedro
    Sonpavde, Guru
    Yu, Evan Y.
    Montgomery, Robert Bruce
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : E440 - E452
  • [48] PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology Concordance Among 3 Commonly Used and Commercially Available Antibodies
    Reis, Henning
    Serrette, Rene
    Posada, Jennifer
    Lu, Vincent
    Chen, Ying-bei
    Gopalan, Anuradha
    Fine, Samson W.
    Tickoo, Swish K.
    Sirintrapun, Sahussapont J.
    Iyer, Gopa
    Funt, Samuel A.
    Teo, Min Yuen
    Rosenberg, Jonathan E.
    Bajorin, Dean E.
    Dalbagni, Guido
    Bochner, Bernard H.
    Solit, David B.
    Reuter, Victor E.
    Al-Ahmadie, Hikmat A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (07) : 920 - 927
  • [49] First-line Immunotherapy in Metastatic Urothelial Carcinoma
    Ghatalia, Pooja
    Zibelman, Matthew
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 45 - 47
  • [50] The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
    Nielsen, Tyler J.
    Varga, Matthew G.
    Cronister, Catherine T.
    Ring, Brian Z.
    Seitz, Robert S.
    Ross, Douglas T.
    Schweitzer, Brock L.
    McGregor, Kimberly
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2075 - 2086
12345